Acetylsalicylic Acid

證據等級: L5

預測適應症: 9 個

Acetylsalicylic Acid: From Analgesia & Antiplatelet to Migraine with Brainstem Aura

One-Sentence Summary

Acetylsalicylic acid (Aspirin) is one of the world's most extensively studied medicines, originally established for analgesia, fever reduction, and antiplatelet cardiovascular protection. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, a rare subtype of migraine with aura involving reversible brainstem symptoms such as dysarthria, vertigo, and diplopia, with 0 clinical trials and 19 publications currently supporting this specific direction.

Quick Overview

Item	Content
Original Indication	Analgesia, antipyretic, antiplatelet (established uses; no Saudi Arabia SFDA registration in current dataset)
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.94%
Evidence Level	L3
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Acetylsalicylic acid (ASA) works primarily by irreversibly inhibiting cyclooxygenase enzymes (COX-1 and COX-2), blocking the production of prostaglandins and thromboxane A₂ (TXA₂). Although formal DrugBank MOA data was not retrieved for this report, ASA's pharmacology is among the most well-characterized in medicine. Its analgesic and anti-inflammatory effects come from reduced prostaglandin synthesis at peripheral and central pain pathways, while its antiplatelet action stems from permanent inactivation of COX-1 in platelets — preventing TXA₂-mediated aggregation and vasoconstriction.

Migraine with brainstem aura (formerly known as basilar-type migraine) is characterized by fully reversible brainstem symptoms — including dysarthria, vertigo, tinnitus, diplopia, and bilateral paresthesias — that develop gradually before the headache phase. The core mechanisms involve cortical spreading depression (CSD) and trigeminovascular system activation with neurogenic inflammation. ASA's COX inhibition reduces prostaglandin synthesis at trigeminal nerve terminals, potentially lowering the neuroinflammatory threshold for aura generation. Critically, ASA's antiplatelet effect may also reduce microemboli that can initiate CSD — a particularly compelling link for the brainstem aura subtype, which shares overlapping vascular and platelet-dependent pathways with conditions such as patent foramen ovale (PFO)-associated migraine.

Clinical plausibility is reinforced by existing evidence: a double-blind RCT (PMID 10448545) demonstrated intravenous ASA efficacy in acute migraine with or without aura, and a retrospective cohort study of 203 migraine-with-aura patients (PMID 25729594) evaluated low-dose ASA specifically for prophylaxis. An observational case series (PMID 29017164) and a 2025 systematic review (PMID 39989443) further explore antithrombotic drugs — including ASA — in migraine prevention. The finding that switching from ASA to clopidogrel (another antiplatelet) reduced migraine-with-aura frequency post-PFO closure (PMID 16103551) also points to platelet-mediated 5-HT dynamics as an active pathway that ASA may modulate in brainstem aura.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10448545	1999	RCT (Double-blind)	Cephalalgia	278 patients with acute migraine (with or without aura) randomized to IV lysine-ASA (equiv. 1 g ASA), sumatriptan 6 mg SC, or placebo; ASA demonstrated significant efficacy in acute migraine relief compared to placebo
39989443	2025	Systematic Review	Headache	Most up-to-date systematic review exploring antithrombotic drugs — including ASA — as migraine preventive therapy; directly addresses the repurposing question
25729594	2014	Retrospective Cohort	Current Health Sciences Journal	203 migraine with aura (MA) patients; 95 (46.8%) treated with low-dose ASA as antiplatelet prophylaxis; evaluated efficacy and tolerability specifically in MA prevention
29017164	2017	Observational Case Series	European Neurology	Observational case series directly assessing aspirin prophylaxis outcomes in migraine with aura patients
25600718	2015	Guideline Review (AHS)	Headache	American Headache Society 2015 evidence assessment of acute migraine pharmacotherapies; classifies ASA among evidence-supported acute migraine treatments
34384631	2021	Review	Revue Neurologique	Comprehensive review of migraine with aura covering CSD as the pivotal aura mechanism, ICHD-III criteria, and pathophysiology — provides mechanistic context for ASA's potential targets
16103551	2005	Clinical Study	Heart	Reports that switching anticoagulation from aspirin to clopidogrel after transcatheter PFO closure significantly reduced migraine with aura episodes; supports platelet-dependent antiplatelet mechanism in migraine with aura
30291554	2018	Review	Current Pain and Headache Reports	Reviews pathophysiologic, epidemiologic, and clinical differences between migraine with and without aura, including risk implications and management considerations
26908949	2016	RCT	European Heart Journal	PRIMA trial: percutaneous PFO closure vs medical therapy in migraine with aura patients refractory to treatment; contextualizes vascular and embolic mechanisms in migraine with aura pathophysiology
33525313	2021	Review	Neurology International	Reviews pharmacological treatment of migraine; identifies aspirin and caffeine-containing combination analgesics as standard of care for mild-to-moderate migraine attacks, including those with aura

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: While no clinical trials are registered specifically for migraine with brainstem aura, a 1999 double-blind RCT confirmed ASA efficacy in acute migraine with aura, retrospective and observational data directly support low-dose ASA prophylaxis in migraine with aura, and a 2025 systematic review has explicitly examined antithrombotics in this setting — collectively placing this TxGNN prediction within a biologically plausible and clinically explored framework. Evidence is currently at L3 (observational studies and systematic review), without a completed Phase 2/3 RCT targeting the brainstem aura subtype specifically.

To proceed, the following is needed:

A prospective RCT or well-powered observational study specifically targeting migraine with brainstem aura (ICHD-III defined) rather than migraine with aura broadly
Retrieval of complete MOA and safety data from DrugBank (DG002) and the SFDA/FDA package insert (DG001), including key warnings, contraindications, and drug–drug interactions
Dose definition: clarify whether prophylactic low-dose (75–100 mg/day) or acute-treatment doses (900–1000 mg) are more appropriate for this indication
Clarification of the Saudi Arabia SFDA registration status: aspirin is universally available globally, but the current dataset shows no SFDA registration — a registry cross-check is recommended before any formal submission pathway is planned
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.